STOCK TITAN

Calumet SEC Filings

CLMT Nasdaq

Welcome to our dedicated page for Calumet SEC filings (Ticker: CLMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Tracking how Calumet converts crude into high-margin specialty waxes one quarter and Sustainable Aviation Fuel the next is no simple read. Footnotes on Montana Renewables subsidies, feedstock hedge swaps, and segment breakouts often push the annual report beyond 300 pages. Stock Titan brings relief with AI-powered summaries that turn dense disclosures into clear highlights, making Calumet SEC filings explained simply more than a promise.

Need the latest Calumet annual report 10-K simplified, a fresh Calumet quarterly earnings report 10-Q filing, or an unexpected Calumet 8-K material events explained? Every form streams from EDGAR in real time. Our platform pinpoints SAF margin shifts, flags covenant changes, and decodes non-GAAP metrics. Real-time alerts surface Calumet Form 4 insider transactions real-time, while comparative tables make Calumet earnings report filing analysis straightforward.

Investors, analysts, and lenders use this page to:

  • Monitor Calumet insider trading Form 4 transactions ahead of calls
  • Review Calumet proxy statement executive compensation for governance checks
  • Streamline research by understanding Calumet SEC documents with AI

You’ll also find downloadable data on Calumet executive stock transactions Form 4, plus narrative insights into turnaround schedules and feedstock costs. Skip the PDF scavenger hunt—our AI delivers comprehensive, real-time coverage so you can focus on decisions, not document digging.

Rhea-AI Summary

Calumet, Inc. (CLMT) announced non‑reliance on its unaudited interim financial statements for the periods ended March 31, 2025 and June 30, 2025, due to a cash flow classification error in the statements of cash flows. The company will restate those periods and file amended Quarterly Reports on Form 10‑Q.

The error misclassified amounts between operating and financing cash flows and had no impact on revenue, net income (loss), or cash and cash equivalents. For the three months ended March 31, 2025, operating cash flow is expected to improve by approximately $81.3 million to $29.3 million of net cash used, with financing cash flow reduced to $109.0 million provided. For the six months ended June 30, 2025, operating cash flow is expected to improve by approximately $76.9 million to $31.1 million of net cash used, with financing cash flow reduced to $111.6 million provided.

Management and the Audit Committee identified a material weakness in internal control over financial reporting related to cash flow statement preparation and review, and concluded disclosure controls and procedures for those periods were ineffective.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
current report
-
Rhea-AI Summary

Calumet, Inc. (CLMT) reported an insider equity change by a director. On June 24, 2025, the director converted 3,796 Restricted Stock Units (RSUs) into an equal number of shares of common stock, shown as transaction code M. The shares were acquired at $0 per share, reflecting a standard RSU settlement rather than a market purchase.

Following the transaction, the director beneficially owns 3,796 shares directly. The filing indicates the RSUs were 100% vested and payable in either shares or cash; the settlement here delivered common stock. No sales were reported, and the derivative RSU balance is now 0.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Amy M. Schumacher, a director of Calumet, Inc. (CLMT), reported receipt of 3,796 restricted stock units on 06/24/2025. The RSUs are described as the economic equivalent of one share each and are 100% vested. Each RSU is payable either in one share of Calumet common stock or the cash value thereof, and the reported acquisition price is $0 (reflecting issuance/settlement of RSUs rather than a cash purchase). The report lists 246,040 shares as the amount of securities beneficially owned following the transaction. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 10/03/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Raymond Paul C, a director of Calumet, Inc. (CLMT), acquired 3,796 restricted stock units on 06/24/2025. The filing shows the RSUs were granted at $0 and are 100% vested, each convertible into one share of common stock or paid in cash. After the reported transaction, the reporting person beneficially owns 19,680 shares of Calumet common stock. The Form 4 was signed by an attorney-in-fact on 10/03/2025. The disclosure is a standard Section 16 statement documenting an insider grant and resulting ownership level.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Jennifer Straumins, a director of Calumet, Inc. (CLMT), received 3,796 Restricted Stock Units on 06/24/2025. The RSUs are fully vested and each unit is the economic equivalent of one share of common stock; they may be settled in one share each or in cash for the cash value. The transaction was coded M and reported as having a $0 price. After the grant, Ms. Straumins is reported to beneficially own 938,385 shares of Calumet common stock. The Form 4 was signed by an attorney-in-fact on 10/03/2025. This filing documents an insider compensation-related grant and confirms the director's current beneficial ownership level.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Daniel J. Sajkowski, a director of Calumet, Inc. (CLMT), reported transactions dated 06/24/2025. He received 3,796 Restricted Stock Units (RSUs) that are 100% vested and economically equivalent to one share each; these RSUs were reported as to be settled in the cash equivalent of common stock. On the same date he reported a disposition of 1,518 shares. After these transactions he beneficially owns 164,237 shares of Calumet common stock. The Form 4 was signed by an attorney-in-fact on 10/03/2025. The filing notes the RSUs may be settled in shares or cash and that the reporter elected to receive 40% of vested RSUs in cash equivalent.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Calumet, Inc. (CLMT) director John G. Boss reported two transactions on 06/24/2025. He received 3,796 Restricted Stock Units that are fully vested and economically equivalent to one share each; the filing shows these RSUs were reported as acquired and may be settled in stock or cash. Separately, he disposed of 1,518 shares in a sale reported the same day. After these transactions the filing shows 27,278 shares beneficially owned following the sale and 28,796 held following the RSU acquisition (table ordering reflects both entries).

The form is filed individually and signed by an attorney-in-fact. The filing clarifies that each RSU equals one common share and that the reporting person elected to receive 40% of vested RSUs in cash equivalent form.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Stephen P. Mawer, a director of Calumet, Inc. (CLMT), reported transactions dated 06/24/2025 on Form 4. He was credited with 7,403 Restricted Stock Units (reported as an acquisition) that are 100% vested and each equals one share or the cash value of one share. He separately reported a sale of 2,962 common shares on the same date. The filings show beneficial ownership rising to 291,055 shares after the RSU acquisition and ending at 288,093 shares following the sale. The reporting person elected to receive 40% of vested RSUs in the cash equivalent of common shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Two Seas Capital LP, Two Seas Capital GP LLC and Sina Toussi report beneficial ownership of 4,497,609 shares of Calumet, Inc. common stock, representing 5.2% of the 86,659,413 shares outstanding referenced for the period ended June 30, 2025. These shares are held by Two Seas Global (Master) Fund LP (the Global Fund).

The filing states that Two Seas Capital (TSC) has sole voting and sole dispositive power over the 4,497,609 shares through its role as investment adviser, that Two Seas Capital GP LLC serves as general partner of TSC, and that Sina Toussi serves as managing member of TSC GP and chief investment officer of TSC. The reporting persons certify the securities are held in the ordinary course of business and not for the purpose of changing or influencing control.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

Calumet, Inc. (CLMT) reported a sharply weaker first half of 2025. Sales were $2,020.5 million for the six months versus $2,139.5 million a year earlier, producing a gross loss of $125.0 million compared with a $142.3 million gross profit last year. Operating results swung to a $149.7 million operating loss for six months and a $309.9 million net loss (versus $80.7 million net loss a year earlier). For the quarter, sales were $1,026.6 million and net loss was $147.9 million, or $1.70 per share on 86.8 million weighted average shares.

Balance sheet and cash flow highlights show total assets of $2,776.4 million and total liabilities of $3,540.5 million, leaving stockholders' equity at a $1,009.7 million deficit. Cash and restricted cash totaled $190.6 million at June 30, 2025. The Company recorded a $457.0 million RINs obligation (current) and had net cash used in operating activities of $108.0 million for the six months. Material transactions included a March 31, 2025 closing of the sale of the industrial portion of Royal Purple for $110.0 million (net proceeds received $95.4 million) producing a $62.2 million gain, and a DOE Loan Guarantee for MRL totaling $1.44 billion with a first tranche disbursement of $781.8 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.62%
Tags
quarterly report

FAQ

What is the current stock price of Calumet (CLMT)?

The current stock price of Calumet (CLMT) is $19.69 as of December 26, 2025.

What is the market cap of Calumet (CLMT)?

The market cap of Calumet (CLMT) is approximately 1.7B.
Calumet

Nasdaq:CLMT

CLMT Rankings

CLMT Stock Data

1.71B
67.65M
22.07%
51.52%
11.57%
Specialty Chemicals
Petroleum Refining
Link
United States
INDIANAPOLIS